|
1
|
Koida A, Tanaka M, Kosaka R, Okuda S, Takei S, Ota S, Yokoyama S, Miyake K, Watanabe H. Canna Starch Improves Intestinal Barrier Function, Inhibits Allergen Uptake, and Suppresses Anaphylactic Symptoms in Ovalbumin-Induced Food Allergy in Mice. Biomolecules 2024; 14:215. [PMID: 38397452 PMCID: PMC10886450 DOI: 10.3390/biom14020215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Revised: 02/08/2024] [Accepted: 02/10/2024] [Indexed: 02/25/2024] Open
Abstract
Edible canna rhizomes contain extremely high levels of resistant starch among cereals and potatoes. We previously showed that feeding canna rhizome starch to mice may increase intestinal barrier function and improve the intestinal environment. Here, we investigated the effects of canna starch intake in a murine food allergy model. Five-week-old female BALB/c mice were divided into four groups: Control and OVA groups fed on the control diet (AIN-93G) ad libitum and Canna and OVA-Canna groups fed on the canna diet (AIN-93G with 10% replaced with canna starch). The OVA and OVA-Canna groups were sensitized to ovalbumin (OVA), and the anaphylactic response was assessed by measuring body temperature. Body temperature was significantly lower in the OVA group than in the non-sensitized group, but no decrease was observed in the OVA-Canna group. Fecal weight, fecal mucin content, and goblet cells of colorectal tissue were significantly increased in the Canna and OVA-Canna groups compared with those in the Control and OVA groups. Allergen uptake into the liver was also increased in the OVA group and decreased in the OVA-Canna group to the same level as in the non-sensitized group. These results indicate that canna starch supplementation in a murine food allergy model suppresses anaphylactic symptoms by improving the intestinal environment and reducing allergen uptake by increasing intestinal barrier function.
Collapse
Affiliation(s)
- Ayaka Koida
- Faculty of Health and Medical Sciences, Aichi Shukutoku University, 2-9 Katahira, Nagakute 480-1197, Aichi, Japan;
| | - Mamoru Tanaka
- Graduate School of Bioscience and Biotechnology, Chubu University, 1200 Matsumoto, Kasugai 487-8501, Aichi, Japan; (R.K.); (S.O.); (S.T.); (K.M.)
- College of Bioscience and Biotechnology, Chubu University, 1200 Matsumoto, Kasugai 487-8501, Aichi, Japan
| | - Rina Kosaka
- Graduate School of Bioscience and Biotechnology, Chubu University, 1200 Matsumoto, Kasugai 487-8501, Aichi, Japan; (R.K.); (S.O.); (S.T.); (K.M.)
| | - Shoei Okuda
- Graduate School of Bioscience and Biotechnology, Chubu University, 1200 Matsumoto, Kasugai 487-8501, Aichi, Japan; (R.K.); (S.O.); (S.T.); (K.M.)
| | - Shiro Takei
- Graduate School of Bioscience and Biotechnology, Chubu University, 1200 Matsumoto, Kasugai 487-8501, Aichi, Japan; (R.K.); (S.O.); (S.T.); (K.M.)
- College of Bioscience and Biotechnology, Chubu University, 1200 Matsumoto, Kasugai 487-8501, Aichi, Japan
| | - Suzuno Ota
- Faculty of Health Science, Suzuka University of Medical Science, 1001-1 Kishioka, Suzuka 510-0293, Mie, Japan;
| | - Sayaka Yokoyama
- Department of Food and Nutritional Environment, Kinjo Gakuin University, 2-1723 Omori, Moriyama-ku, Nagoya 463-8521, Aichi, Japan;
| | - Kaho Miyake
- Graduate School of Bioscience and Biotechnology, Chubu University, 1200 Matsumoto, Kasugai 487-8501, Aichi, Japan; (R.K.); (S.O.); (S.T.); (K.M.)
| | - Hiroyuki Watanabe
- Faculty of Nutrition, University of Kochi, 2751-1 Ike, Kochi 781-8515, Kochi, Japan;
| |
Collapse
|
|
2
|
Yamada Y, Yokooji T, Kunimoto K, Inoguchi K, Ogino R, Taogoshi T, Morita E, Matsuo H. Hypoallergenic Wheat Line (1BS-18H) Lacking ω5-Gliadin Induces Oral Tolerance to Wheat Gluten Proteins in a Rat Model of Wheat Allergy. Foods 2022; 11:foods11152181. [PMID: 35892765 PMCID: PMC9329752 DOI: 10.3390/foods11152181] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Revised: 07/13/2022] [Accepted: 07/19/2022] [Indexed: 12/10/2022] Open
Abstract
The early ingestion of food can prevent the onset of food allergy related to inducing oral tolerance (OT). We developed the Hokushin wheat line as a hypoallergenic wheat (1BS-18H) lacking ω5-gliadin, a major allergen of wheat-dependent exercise-induced anaphylaxis (WDEIA). The 1BS-18H wheat had lower ability of sensitization for ω5-gliadin compared with Hokushin wheat. Here, we evaluated the induction of OT to gluten and ω5-gliadin by the early consecutive ingestion of 1BS-18H gluten using a rat model of wheat allergy. Rats were subcutaneously immunized with commercial gluten or native ω5-gliadin following the daily oral administration of gluten. The daily oral administration of 1BS-18H gluten for 5 days before immunization suppressed the increase in gluten- or ω5-gliadin-specific IgE and IgG1 antibodies induced by immunization to a level similar to Hokushin gluten. Intravenous challenge with gluten or ω5-gliadin did not decrease the rectal temperature in rats with OT induced by 1BS-18H or Hokushin gluten, although it was decreased in non-OT rats. In conclusion, the early consecutive ingestion of 1BS-18H wheat before sensitization induced OT to gluten and ω5-gliadin. These findings support the benefit of 1BS-18H wheat to prevent wheat allergy including WDEIA by consecutive ingestion in humans.
Collapse
Affiliation(s)
- Yukinori Yamada
- Department of Pharmaceutical Services, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan; (Y.Y.); (K.K.); (K.I.); (T.T.); (H.M.)
| | - Tomoharu Yokooji
- Department of Pharmaceutical Services, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan; (Y.Y.); (K.K.); (K.I.); (T.T.); (H.M.)
- Department of Frontier Science for Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan;
- Correspondence: ; Tel.: +81-82-257-5295
| | - Kyohei Kunimoto
- Department of Pharmaceutical Services, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan; (Y.Y.); (K.K.); (K.I.); (T.T.); (H.M.)
| | - Koki Inoguchi
- Department of Pharmaceutical Services, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan; (Y.Y.); (K.K.); (K.I.); (T.T.); (H.M.)
| | - Ryohei Ogino
- Department of Frontier Science for Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan;
| | - Takanori Taogoshi
- Department of Pharmaceutical Services, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan; (Y.Y.); (K.K.); (K.I.); (T.T.); (H.M.)
| | - Eishin Morita
- Department of Dermatology, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan;
| | - Hiroaki Matsuo
- Department of Pharmaceutical Services, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan; (Y.Y.); (K.K.); (K.I.); (T.T.); (H.M.)
| |
Collapse
|